NSCLC

Thermo Fisher Scientific, Illumina, Eli Lilly, Celgene, and Roche/Genentech have committed their expertise and funding to build a lung cancer registry.

Researchers from a SU2C-sponsored study compared tissue biopsy and liquid biopsy for detecting the T790M mutation of the EGFR gene in a cohort of NSCLC patients.

FDA has approved BMS' Opdivo with a test to guide treatment strategies, but according to the drug label testing isn't required to identify who should receive the drug.

Dako developed the PD-L1 CDx very specifically to fit Keytruda's mechanism and patients' outcomes to the drug.

The test is for determining whether a patient's tumor expresses the PD-L1 protein and is likely to respond to Merck's drug Keytruda, which the FDA also approved today.

Researchers from Stanford University have developed a nine-gene panel and a composite risk model to determine prognosis in non-small cell lung cancer.

Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.

The test was approved for use with Iressa to determine those patients who would benefit by being treated with the drug. 

Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.

Guardant's test will be used to detect mutations associated with acquired resistance to EGFR-inhibiting therapies and to guide further treatment strategies in a study of 600 patients.

Pages

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.